Syndax Pharmaceuticals (SNDX) Common Equity (2015 - 2026)

Syndax Pharmaceuticals' Common Equity history runs 12 years deep, the most recent figure standing at $41.6 million for Q1 2026.

• In Q1 2026, Common Equity fell 80.65% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $41.6 million (down 80.65% YoY), while the FY2025 annual figure was $64.6 million, down 77.57% from the prior year.
• Common Equity was $41.6 million for Q1 2026 at Syndax Pharmaceuticals, down from $64.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $554.2 million in Q4 2023 to a low of $41.6 million in Q1 2026.
• Historically, Common Equity has averaged $321.5 million across 5 years, with a median of $361.9 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Common Equity jumped 69.9% in 2022, then slumped 80.65% in 2026.
• A 5-year view of Common Equity shows it stood at $467.4 million in 2022, then grew by 18.56% to $554.2 million in 2023, then sank by 48.01% to $288.1 million in 2024, then slumped by 77.57% to $64.6 million in 2025, then sank by 35.6% to $41.6 million in 2026.
• The last three Common Equity figures came in at $41.6 million (Q1 2026), $64.6 million (Q4 2025), and $115.4 million (Q3 2025), per Business Quant data.